Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Short Title: TARA-002

Enrollment Status: Recruiting

NCT #: NCT05951179

Specialty Area: Oncology

Condition Studied: Non-Invasive Bladder Cancer

Age Groups: Adult; Older Adult

Phase: II

Study Information

Summary / Purpose

To find out if TARA-002, given directly into the bladder, is safe and effective in treating high-grade non-muscle invasive bladder cancer, especially in patients who are BCG-naive, BCG-exposed, or BCG-unresponsive.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with high-grade carcinoma in situ (CIS) of the bladder, with or without Ta/T1 disease
Persistent or recurrent CIS who are BCG-unresponsive within 12 months of completing adequate BCG therapy
No penicillin allergy

What's Involved

Participation in the study will include:

Intravesical instillation of the investigational therapy TARA-002 directly into the bladder
Regular cystoscopy and pathology assessments to monitor response to treatment
Blood and urine tests to monitor your health and treatment effects
Questionnaires

Principal Investigator

Eric Kim, MD

Urology

A Member of

(775) 982–5000

Renown Urology Care

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT05951179

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews